Avadel Pharmaceuticals (NASDAQ:AVDL) released its quarterly earnings results on Friday. The company reported ($0.46) EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.06, MarketWatch Earnings reports. Avadel Pharmaceuticals had a negative return on equity of 86.08% and a negative net margin of 34.91%. The company had revenue of $20.92 million for the quarter.
Shares of NASDAQ AVDL traded down $0.33 during mid-day trading on Friday, hitting $1.67. The company had a trading volume of 473,107 shares, compared to its average volume of 131,943. The stock has a market cap of $74.02 million, a P/E ratio of 5.39 and a beta of 1.81. The company has a current ratio of 3.15, a quick ratio of 3.02 and a debt-to-equity ratio of 1.74. Avadel Pharmaceuticals has a 1-year low of $1.61 and a 1-year high of $7.97.
Several brokerages have recently issued reports on AVDL. ValuEngine upgraded Avadel Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, January 2nd. LADENBURG THALM/SH SH cut Avadel Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Friday, February 8th. Finally, Zacks Investment Research upgraded Avadel Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, January 7th. One research analyst has rated the stock with a sell rating and six have assigned a hold rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $6.42.
TRADEMARK VIOLATION NOTICE: “Avadel Pharmaceuticals (AVDL) Issues Earnings Results” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another website, it was illegally copied and republished in violation of United States and international copyright laws. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2019/03/16/avadel-pharmaceuticals-avdl-issues-earnings-results.html.
Avadel Pharmaceuticals Company Profile
Avadel Pharmaceuticals plc develops and commercializes pharmaceutical products primarily for treating urology and sleep medicines in the United States, France, and Ireland. Its commercial products that are used in the hospital setting include Bloxiverz, a drug used in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; Vazculep, a phenylephrine hydrochloride injection that is used for the treatment of hypotension occurring in the setting of anesthesia; and Akovaz, an ephedrine sulfate injection for treating hypotension, as well as Noctiva for treating nocturia due to nocturnal polyuria.
Further Reading: Capital gains and your 401(k) or IRA
Receive News & Ratings for Avadel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avadel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.